Nivolumab (Opdivo) is a humanized monoclonal antibody that is approved by the U.S. Food and Drug Administration for the treatment of patients with unresectable or metastatic melanoma. Nivolumab binds to the human cell surface receptor PD-1 (Programmed Ce
Clonality:
Monoclonal
Clone Designation:
[6G5H2E6]
Purity:
Protein A chromatography
Form:
Purified
Antibody Type:
Monoclonal Antibody
Application Dilute:
ELISA detection: 0.01-0.1 µg/ml
* VAT and and shipping costs not included. Errors and price changes excepted